Medroxyprogesterone 17-Acetate + Medroxyprogesterone 17-Acetate

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Contraception

Conditions

Contraception

Trial Timeline

Mar 1, 2010 → Nov 1, 2012

NCT ID

NCT01019369

About Medroxyprogesterone 17-Acetate + Medroxyprogesterone 17-Acetate

Medroxyprogesterone 17-Acetate + Medroxyprogesterone 17-Acetate is a pre-clinical stage product being developed by Pfizer for Contraception. The current trial status is completed. This product is registered under clinical trial identifier NCT01019369. Target conditions include Contraception.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01019369	Pre-clinical	Completed	Mar 1, 2010	Nov 1, 2012	Contraception

Competing Products

20 competing products in Contraception

See all competitors

Product	Company	Stage	Hype Score
Injection Cyclofem	Sun Pharmaceutical	Phase 1/2	41
Relugolix Combination Therapy	Sumitomo Pharma	Phase 3	77
Transdermal Contraceptive System + Norgestimate-containing oral contraceptives with EE	Johnson & Johnson	Pre-clinical	23
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.	Johnson & Johnson	Phase 1	33
norelgestromin + ethinyl estradiol	Johnson & Johnson	Phase 3	77
norelgestromin + ethinyl estradiol; triphasil.	Johnson & Johnson	Phase 3	77
norelgestromin + ethinyl estradiol; mercilon	Johnson & Johnson	Phase 3	77
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).	Johnson & Johnson	Phase 1	33
EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE	Johnson & Johnson	Phase 1	33
Monophasic or triphasic Oral contraceptive tablet + Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE	Johnson & Johnson	Pre-clinical	23
Norgestimate/Ehinyl Estradiol; Folic acid.	Johnson & Johnson	Phase 1	33
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).	Johnson & Johnson	Phase 1	33
oral ulipristal acetate	Merck	Phase 1	33
Etonogestrel contraceptive implant	Merck	Approved	85
Rifampin 600 MG	Merck	Approved	85
Long Acting Reversible Contraception (LARC)	Merck	Approved	85
Etonogestrel contraceptive implant	Merck	Approved	85
Sayana Press	Pfizer	Approved	84
Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg	Pfizer	Phase 3	76
Depo-Provera Contraceptive Injection - DP150CI	Pfizer	Approved	84

Other Products from Pfizer